Literature DB >> 36221010

Trends in Biochemical Parameters, Healthcare Resource and Medication Use in the 5 Years Preceding IBD Diagnosis: A Health Maintenance Organization Cohort Study.

Nathaniel A Cohen1,2,3, Efrat Kliper4, Noa Zamstein4, Tomer Ziv-Baran5, Matti Waterman6,7, Gabriel Hodik8,9, Amir Ben Tov8,9,10, Revital Kariv8,9,10.   

Abstract

BACKGROUND: Few data describing pre-diagnosis changes in patients with inflammatory bowel disease (IBD) exist. We aimed to determine if there is a pattern of change in use of health resources, medications and laboratory results in the years preceding diagnosis.
METHODS: This retrospective study used electronic medical records of Maccabi Health Services (MHS). Patients with IBD ≥ 16 years of age and minimum of 5-years follow-up were identified by entry into the MHS IBD registry and included in the analysis. Demographic, clinical, medication and laboratory data were collected. Generalized estimating equation model was applied to study trends and compare between years.
RESULTS: This study included 5643 patients with IBD. Of these, 3039 (53.8%) had Crohn's disease (CD), 2322 (41.1%) had ulcerative colitis (UC) and 282 (5%) had indeterminate colitis (IC). Laboratory parameters including white blood cells, platelets and C-reactive protein showed significant increases while haemoglobin and mean cell volume showed significant decreases in mean values in the 2 years prior to diagnosis with stable values prior to that (p < 0.0001). Parameters such as creatinine, total protein and albumin showed significant, progressive decreases in mean values starting 5 years prior to diagnosis (p < 0.0001). Patients with CD had distinct laboratory trends when compared with patients with UC.
CONCLUSIONS: Changes in laboratory parameters, healthcare service and medication use occur during the 5-year period before IBD diagnosis. These data can have future clinical applicability by developing a composite score and referral algorithm introducing red flags into primary care visits and appropriate referral for specialist care.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; Pre-diagnosis; Prediction; Ulcerative colitis

Year:  2022        PMID: 36221010     DOI: 10.1007/s10620-022-07714-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  24 in total

1.  The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?

Authors:  Twila Burgmann; Ian Clara; Lesley Graff; John Walker; Lisa Lix; Patricia Rawsthorne; Cory McPhail; Linda Rogala; Norine Miller; Charles Noah Bernstein
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04-17       Impact factor: 11.382

2.  Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.

Authors:  E Israeli; I Grotto; B Gilburd; R D Balicer; E Goldin; A Wiik; Y Shoenfeld
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

3.  Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis.

Authors:  Gary R Lichtenstein; Ahva Shahabi; Seth A Seabury; Darius N Lakdawalla; Oliver Díaz Espinosa; Sarah Green; Michelle Brauer; Robert N Baldassano
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-18       Impact factor: 11.382

4.  Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis.

Authors:  Joana Torres; Francesca Petralia; Takahiro Sato; Pei Wang; Shannon E Telesco; Rok Seon Choung; Richard Strauss; Xiao-Jun Li; Renee M Laird; Ramiro L Gutierrez; Chad K Porter; Scott Plevy; Fred Princen; Joseph A Murray; Mark S Riddle; Jean-Frederic Colombel
Journal:  Gastroenterology       Date:  2020-03-09       Impact factor: 22.682

Review 5.  Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease.

Authors:  A Sainsbury; R V Heatley
Journal:  Aliment Pharmacol Ther       Date:  2005-03-01       Impact factor: 8.171

6.  Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease.

Authors:  M E Kanof; A M Lake; T M Bayless
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

7.  Presenting features of inflammatory bowel disease in Great Britain and Ireland.

Authors:  A Sawczenko; B K Sandhu
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

8.  Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease.

Authors:  Paul Lochhead; Hamed Khalili; Ashwin N Ananthakrishnan; James M Richter; Andrew T Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2016-02-01       Impact factor: 11.382

9.  Development of the Crohn's disease digestive damage score, the Lémann score.

Authors:  Benjamin Pariente; Jacques Cosnes; Silvio Danese; William J Sandborn; Maïté Lewin; Joel G Fletcher; Yehuda Chowers; Geert D'Haens; Brian G Feagan; Toshifumi Hibi; Daniel W Hommes; E Jan Irvine; Michael A Kamm; Edward V Loftus; Edouard Louis; Pierre Michetti; Pia Munkholm; Tom Oresland; Julian Panés; Laurent Peyrin-Biroulet; Walter Reinisch; Bruce E Sands; Juergen Schoelmerich; Stefan Schreiber; Herbert Tilg; Simon Travis; Gert van Assche; Maurizio Vecchi; Jean-Yves Mary; Jean-Frédéric Colombel; Marc Lémann
Journal:  Inflamm Bowel Dis       Date:  2010-11-28       Impact factor: 5.325

10.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Authors:  David M Faleck; Adam Winters; Shreya Chablaney; Preeti Shashi; Joseph Meserve; Aaron Weiss; Satimai Aniwan; Jenna L Koliani-Pace; Gursimran Kochhar; Brigid S Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Varun Kesar; Karen Lasch; Michelle Luo; Matthew Bohm; Sashidhar Varma; Monika Fischer; David Hudesman; Shannon Chang; Dana Lukin; Keith Sultan; Arun Swaminath; Nitin Gupta; Corey A Siegel; Bo Shen; William J Sandborn; Sunanda Kane; Edward V Loftus; Bruce E Sands; Jean-Frederic Colombel; Parambir S Dulai; Ryan Ungaro
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-06       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.